EPS Accretion versus Value Creation in the Nirmal Auto Components Bid
Sarvottam Engineering Ltd trades at ₹410 per share with 62 crore shares outstanding, PAT of ₹310 crore and therefore a P/E of 8.2, and carries no debt. It is bidding for Nirmal Auto Components: EBITDA ₹180 crore, depreciation ₹45 crore, debt ₹420 crore, tax 25.17%. Nirmal's promoters want ₹1,450 crore of equity value, in cash, for 100% of the company. Advisers estimate pre-tax synergies of ₹55 crore at full run-rate, with 60% achieved in year one, and ₹80 crore of cost to achieve spread over two years. Financing is 60% debt at 9.5% and 40% new shares issued at ₹410. WACC is 12%. The board is being urged to sign because 'the deal is over 20% EPS accretive and cheaper than our own multiple'. A large institutional shareholder has written that it will vote against any deal priced above 8x EBITDA.
1. Compute the year-one and full-run-rate EPS impact and explain why accretion alone is not a reason to proceed.
Read the worked answer
Deal arithmetic
- Equity value ₹1,450 crore; debt assumed ₹420 crore; enterprise value = ₹1,870 crore = 10.4x EBITDA
- Target EBIT = 180 − 45 = ₹135 crore; NOPAT = 135 × 0.7483 = ₹101.0 crore; implied P/E = 1,450/101.0 = 14.35
- New shares issued = 0.40 × 1,450/410 = 1.4146 crore
- Debt raised = 0.60 × 1,450 = ₹870 crore; interest = ₹82.65 crore; after tax ₹61.85 crore
- After-tax synergies: full run-rate 55 × 0.7483 = ₹41.16 crore; year one 60% = ₹24.70 crore
Year one: PAT = 310 + 101.0 + 24.70 − 61.85 = ₹373.85 crore; shares = 63.4146 crore; EPS = ₹5.90 against ₹5.00 standalone - 18% accretive. Full run-rate: PAT = ₹390.31 crore; EPS = ₹6.16 - 23% accretive.
Why accretion is the wrong test. EPS mixes a financing decision with a valuation decision. Here the accretion comes from two sources that have nothing to do with value: cheap after-tax debt (7.1%) and the fact that Nirmal's earnings are being bought partly with Sarvottam's paper. Note the direction of the multiple trade - Sarvottam is issuing shares on a P/E of 8.2 to buy earnings on a P/E of 14.35, which is dilutive on the share-funded slice; only the debt slice and the synergies rescue the number. If the same deal were funded entirely with shares, EPS would be 411.2/65.537 = ₹6.27 on full synergies but ₹5.77 in year one - a very different story to tell the board. Accretion measures accounting arithmetic; value depends on the return on the ₹1,870 crore being invested.
2. Test whether the deal creates value, and derive the maximum price Sarvottam can justify paying.
Read the worked answer
Return on incremental capital
- Incremental NOPAT at full synergies = 101.0 + 41.16 = ₹142.16 crore
- Incremental capital employed (EV paid) = ₹1,870 crore
- ROIC = 142.16/1,870 = 7.6% against a WACC of 12%
A 4.4 percentage point shortfall on ₹1,870 crore is roughly ₹82 crore of economic loss every year, about ₹685 crore of value at a 12% capitalisation. Paying 10.4x EBITDA for a business whose standalone returns do not cover its cost of capital cannot be fixed by leverage.
Value the synergies properly
- Perpetuity value of after-tax synergies = 41.16/0.12 = ₹343 crore
- Less cost to achieve ₹80 crore (undiscounted, conservative) = ₹263 crore of net synergy value
Maximum price = standalone value of Nirmal + net synergy value. The shareholder's 8x EBITDA benchmark gives standalone EV = 8 × 180 = ₹1,440 crore (equity ₹1,020 crore). Maximum EV ≈ 1,440 + 263 = ₹1,703 crore, i.e. about 9.5x EBITDA, or roughly ₹1,283 crore of equity - about ₹167 crore below the asking price.
Sensitivity. Synergies would have to reach about ₹87 crore pre-tax (58% above the estimate) for the 10.4x price to earn 12%; alternatively the price must fall by at least 9–10% to make the arithmetic work. Given that synergy forecasts in auto components routinely suffer 30–40% shortfalls, the base case is value-destructive even though the EPS chart looks attractive.
3. Advise the board on how to respond to the bid and to the shareholder letter, including deal structure.
Read the worked answer
Recommendation: do not sign at ₹1,450 crore of equity value. Present the board with three routes.
- Re-price and re-structure. Offer an EV of about ₹1,500–1,550 crore (8.3–8.6x EBITDA) with 50% of the consideration deferred into a two-year earn-out tied to realised synergies and to Nirmal retaining its top three customer contracts. This shifts synergy risk to the seller, who is best placed to underwrite it, and answers the shareholder's 8x objection directly.
- Re-scope the deal. Buy only the profitable product lines and the customer contracts, leaving the ₹420 crore of debt and the weaker assets with the seller. Smaller cheque, cleaner returns.
- Walk away. With no debt on Sarvottam's balance sheet and a 12% WACC, a buyback or a greenfield capacity expansion inside its own business may earn more than 7.6%.
Answering the shareholder. Do not dismiss the letter. Publish the value bridge: standalone value, synergy value, price paid, and the ROIC/WACC spread under the base and downside cases. If the board still wants the deal, seek a specific waiver from the shareholder rather than proceeding on an assumption of support - a hostile institutional vote on a related acquisition is a governance problem in itself.
Financing caution. The 60% debt structure takes leverage from nil to roughly 1.4x combined EBITDA and adds ₹83 crore of annual interest against combined EBITDA of about ₹600 crore. Check the interest cover covenant before, not after, signing, and confirm the acquisition debt does not cross-default the existing facilities.